News
Medtronic (NYSE: MDT) today announced a new interim analysis evaluating automated sacral neuromodulation (SNM) therapy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback